Clinical trials: Neuroprotective Drugs
Multiple Sclerosis
Lipoic Acid for Progressive Multiple Sclerosis (MS)
The purpose of the study is to determine if lipoic acid can preserve mobility and protect the brain in progressive forms of multiple sclerosis.
- Trial name
- LAPMS (NCT03161028)
- Testing
- Lipoic acid
- Where
- 11 sites in United States, Canada
- Volunteers
- 115 people
- Sponsor
- VA Office of Research and Development
Subarachnoid Aneurysm Hemorrhage
Minocycline as Neuroprotectant After Aneurysmal Subarachnoid Hemorrhage
The purpose of this study is to determine the safety and efficacy of a drug minocycline in improving outcomes at 3 months after rupture of an aneurysm in the head.
- Trial name
- NCT02113176
- Testing
- Minocycline
- Where
- United States
- Sponsor
- University at Buffalo
TBI (Traumatic Brain Injury)
Evaluation of the Effect of Neuroprotective Drug on Treatment Result in Patients After Traumatic Brain Injury
Traumatic Brain Injury TBI is one of the most common causes of death and recovery failure worldwide. Each element of treatment, starting from possible surgical treatment, patient monitoring and neuroprotective treatment, can be…
- Trial name
- NCT05807503
- Testing
- Cerebrolysin
- Where
- Poland
- Volunteers
- 56 people
- Sponsor
- Pomeranian Medical University Szczecin
Out-of-hospital Cardiac Arrest (OHCA)
Ketamine Sedation As Neuroprotective Agent Following Out-of-hospital Cardiac Arrest
OHCA is a critical medical emergency with significant mortality and morbidity primarily due to hypoxic-ischemic brain injury (HIBI).
- Trial name
- KETOHCA (NCT06744361)
- Testing
- esketamine hydrochloride, propofol
- Where
- 2 sites in Denmark
- Volunteers
- 282 people
- Sponsor
- Christian Hassager
Acute Ischemic Stroke
Comparative Effectiveness of Neuroprotectants on Acute Ischemic Stroke
The primary objective of this study is to compare effectiveness of five different neuroprotectants, including butylphthalide, edaravone, citicoline, cerebrolysin, and piracetam, among patients with acute ischemic stroke.
- Trial name
- CER (NCT01556854)
- Where
- China
- Volunteers
- 20,000 people
- Sponsor
- yongjun wang
Acute Stroke
Endovascular Magnesium Sampling in Acute Stroke
This investigation will address the safety and feasibility of distal, intra-arterial sampling through endovascular access, in acute stroke patients.
- Trial name
- NCT01502748
- Testing
- endovascular sampling
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- University of Southern California
Stroke, Acute
Study of a Neuroprotective Drug to Limit the Extent of Damage From an Ischemic Stroke
The primary aim of this study is to find out which of 4 different doses of minocycline are safe and well tolerated so that we will know the optimal dose to test in future patients.
- Trial name
- MINOS (NCT00630396)
- Testing
- Minocycline
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- David Hess, MD
Comatose Survivors of Cardiac Arrest
High Dose of Erythropoietin Analogue After Cardiac Arrest
The investigators hypothesised that the neuroprotective effects of erythropoietin and its analogues could lead to an improve outcome after cardiac arrest.
- Trial name
- Epo-ACR-02 (NCT00999583)
- Testing
- EPOETINE ALPHA, Control arm
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cognitive Disorders, HIV Infections
A Study of Decreased Mental Function Associated With HIV
The purpose of this study is to compare pictures of the brain of HIV-infected people with memory problems before and after treatment with selegiline. Selegiline is the study drug received through A5090.
- Trial name
- NCT00027040
- Testing
- Selegiline hydrochloride
- Where
- 12 sites in United States
- Volunteers
- 90 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ischemic Stroke
Study of Efficacy and Safety of MEXIDOL® in Ischemic Stroke Therapy
The purpose of this study is to evaluate the efficacy and safety of long-term sequential therapy with Mexidol® in long-term sequential treatment of patients in the acute and early recovery periods of hemispheric ischemic stroke…
- Trial name
- EPICA (NCT02793687)
- Testing
- Mexidol
- Where
- 11 sites in Russia
- Volunteers
- 150 people
- Sponsor
- Pharmasoft
Acute Stroke
Intra-arterial Magnesium Administration for Acute Stroke
Stroke is the second leading cause of death and the leading cause of adult disability worldwide. This investigation will address the safety and feasibility of directed, intra-arterial Magnesium measurement and therapy, through…
- Trial name
- NCT01502761
- Testing
- Magnesium Sulfate
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- University of Southern California
Acute Ischemic Stroke
Efficacy and Safety of QD202 in Participants With Acute Ischemic Stroke Undergoing Thrombolysis Excluding Endovascular Thrombectomy
This is a randomized, double-blinded, placebo-controlled study investigating the safety and efficacy of QD202 injection in patients with acute ischemic stroke undergoing thrombolysis excluding endovascular thrombectomy.
- Trial name
- NCT07581210
- Testing
- QD202
- Where
- 14 sites in China
- Volunteers
- 120 people
- Sponsor
- Shanghai QuietD Biotechnology Co., Ltd.
Multiple Sclerosis, Multiple Sclerosis, Primary Progressive
Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis
This study evaluates the effectiveness of N-acetyl cysteine (NAC) in the treatment of progressive multiple sclerosis. Half of the patients will receive NAC, while the other half will receive a placebo.
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Trial name
- NACPMS (NCT05122559)
- Testing
- N-acetyl cysteine
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Emmanuelle Waubant, MD PhD